Internationally renowned scientists in the field of personalized and precision medicine gather together online at PEMED 2021, chaired by the Josep Carreras Leukeaemia Research Institute, to share the latest discoveries on how individual variability modifies available treatments to complex diseases.
The first CAR-T immunotherapy drug produced entirely in Sant Pau (academic) and administered to the first patient is part of a pioneering clinical trial in Europe of CAR-T phase I / II immunotherapy for the autologous treatment of classical Hodgkin lymphoma and relapsed / refractory CD30 + non-Hodgkin T CD30 + lymphoma, funded by the Carlos III Health Institute and the Josep Carreras Leukaemia Foundation.
The trial, with the participation of the Josep Carreras Leukemia Research Institute, shows that CAR-T technology is effective in multiple myeloma patients who have already exhausted their default treatment options.
The international symposium “The immune system: in sickness and in health”, organized by the junior group leader committee of the Josep Carreras Institute, joins 16 of the best emerging talents working on the immune system in an event with over 400 registrations.
The mission of the Single Cell Unit is to facilitate academic research by offering services based on cutting-edge single-cell and spatial genomics technologies.
The Joint Cytometry Unit, formed by the Josep Carreras Leukemia Research Institute and the company Cytognos S.L., has developed a new commercial reagent that helps determine the prognosis of patients with Acute Myeloid Leukemia at the time of diagnosis.
The Josep Carreras Leukaemia Research Institute signs a memorandum of understanding with the National Cancer Institute of the National Institutes of Health (NIH).
Researchers from the Myelodysplastic Syndrome group at Josep Carreras Leukaemia Research Institute describe the diversity of cancer cell populations coexisting in patients of the disease, using single cell resolution for the first time.
This conference brings together international emerging leaders in the fields of immunology and leukaemia and highlights the latest advances in immunogenomics, immunotherapy and degeneration of the immune system during ageing.
Researchers from the Josep Carreras Leukaemia Research Institute have participated in a study analyzing the genomic characteristics of over two thousand Myelodysplastic Syndrome patients concluding that, together with the IPSS-R score, this information improves the definition of prognosis in terms of survival and acute leukemia transformation.
